Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CDP 860

Drug Profile

CDP 860

Alternative Names: anti-PDGF beta receptor antibody; anti-platelet derived growth factor beta receptor antibody

Latest Information Update: 30 Mar 2004

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Washington; ZymoGenetics
  • Developer Nektar Therapeutics
  • Class Antineoplastics
  • Mechanism of Action Intercellular signalling peptide and protein inhibitors; Platelet-derived growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer; Coronary artery restenosis

Most Recent Events

  • 30 Mar 2004 Discontinued - Phase-II for Cancer in United Kingdom (unspecified route)
  • 16 Jun 2003 CDP 860 is available for partnering (http://www.celltechgroup.com/)
  • 29 Oct 2002 Inhale Therapeutic Systems and Celltech have entered into a licensing, manufacturing and supply agreement for CDP 860
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top